Tonix Pharmaceuticals CEO Seth Lederman joins Proactive's Natalie Stoberman to share the findings of two publications in the American Journal of Transplantation that demonstrate how the company's TNX-1500 monoclonal antibody product candidate aided in the prevention of organ rejection for kidney and heart transplants.
Lederman says these animal studies found that TNX-1500 retains activity to prevent rejection and preserve graft function. He adds that Tonix expects to start a first-in-human Phase 1 study in the second quarter of 2023 of TNX-1500 for prophylaxis of organ rejection in adult patients receiving a kidney transplant.
Proactive Studio
+1 347-449-0879
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.18 |
| Daily Change: | 0.04 27.23 |
| Daily Volume: | 90,356,456 |
| Market Cap: | US$18.500M |
October 16, 2024 October 08, 2024 September 27, 2024 | |
Else Nutrition is changing the face of early childhood nutrition with clean, sustainable, plant-based products. The company has developed the world’s first whole plant-based infant formula that is targeting the $100+ billion global...
CLICK TO LEARN MORE
UGE International develops, owns, and operates commercial and community solar projects in the United States and strategic markets abroad. Our distributed energy solutions deliver cheaper, cleaner energy to businesses and consumers...
CLICK TO LEARN MORE